Health-related quality-of-life findings for the prostate cancer prevention trial
Department of Quantitative Health Sciences
Quality of Life; Health Status; Prostatic Neoplasms
Epidemiology | Health Services Research | Neoplasms
BACKGROUND: The Prostate Cancer Prevention Trial (PCPT)-a randomized placebo-controlled study of the efficacy of finasteride in preventing prostate cancer-offered the opportunity to prospectively study effects of finasteride and other covariates on the health-related quality of life of participants in a multiyear trial.
METHODS: We assessed three health-related quality-of-life domains (measured with the Health Survey Short Form-36: Physical Functioning, Mental Health, and Vitality scales) via questionnaires completed by PCPT participants at enrollment (3 months before randomization), at 6 months after randomization, and annually for 7 years. Covariate data obtained at enrollment from patient-completed questionnaires were included in our model. Mixed-effects model analyses and a cross-sectional presentation at three time points began at 6 months after randomization. All statistical tests were two-sided.
RESULTS: For the physical function outcome (n = 16 077), neither the finasteride main effect nor the finasteride interaction with time were statistically significant. The effects of finasteride on physical function were minor and accounted for less than a 1-point difference over time in Physical Functioning scores (mixed-effect estimate = 0.07, 95% confidence interval [CI] = -0.28 to 0.42, P = .71). Comorbidities such as congestive heart failure (estimate = -5.64, 95% CI = -7.96 to -3.32, P < .001), leg pain (estimate = -2.57, 95% CI = -3.04 to -2.10, P < .001), and diabetes (estimate = -1.31, 95% CI = -2.04 to -0.57, P < .001) had statistically significant negative effects on physical function, as did current smoking (estimate = -2.34, 95% CI = -2.97 to -1.71, P < .001) and time on study (estimate = -1.20, 95% CI = -1.36 to -1.03, P < .001). Finasteride did not have a statistically significant effect on the other two dependent variables, mental health and vitality, either in the mixed-effects analyses or in the cross-sectional analysis at any of the three time points.
CONCLUSION: Finasteride did not negatively affect SF-36 Physical Functioning, Mental Health, or Vitality scores.
DOI of Published Version
J Natl Cancer Inst. 2012 Sep 19;104(18):1373-85. Epub 2012 Sep 12. Link to article on publisher's site
Journal of the National Cancer Institute
Moinpour, Carol M.; Darke, Amy K.; Donaldson, Gary W.; Cespedes, Duane; Johnson, Christine R.; Ganz, Patricia A.; Patrick, Donald L.; Ware, John E. Jr.; Shumaker, Sally A.; Meyskens, Frank L.; and Thompson, Ian M. Jr., "Health-related quality-of-life findings for the prostate cancer prevention trial" (2012). Quantitative Health Sciences Publications and Presentations. 1060.